Showing 21-30 of 1113 results for "".
- Juvederm Volbella XC Scores FDA Nod for Undereye Hollowshttps://practicaldermatology.com/news/juvederm-volbella-xc-scores-fda-nod-for-undereye-hollows/2461071/The US Food and Drug Administration has given its nod to Allergan Aesthetics, Juvederm Volbella XC for improvement of infraorbital hollows in adults over the age of 21. Per FDA requirement for this new indication, Allergan Aesthetics is providing a product training program for all interested pro…
- EWG: UVA Protection of Most Sunscreens Just 25 Percent of Touted SPFhttps://practicaldermatology.com/news/ewg-most-sunscreens-comprise-just-25-percent-of-touted-spf/2460962/Many sunscreens offer just a quarter of their stated SPF protection against ultraviolet A rays, a new Environmental Working Group (EWG) study finds. For the study, EWG scientists tested 51 sunscreens with SPF between 15 and 110 to assess their broad-spectrum protection against both types of UV ray…
- Janssen Seeks FDA Nod for Stelara in Juvenile PsAhttps://practicaldermatology.com/news/janssen-seeks-fda-nod-for-stelara-in-juvenile-psa/2460949/Janssen is seeking expanded approval of Stelara (ustekinumab) for pediatric patients aged five and older with juvenile psoriatic arthritis (jPsA). The company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA). The filing is supported by ex…
- C-Jun Protein May Play Role in Psoriasis Developmenthttps://practicaldermatology.com/news/c-jun-protein-may-play-role-in-psoriasis-development/2460753/The "c-Jun" protein may play a major role in the development of psoriasis, but inhibiting this protein may alleviate symptoms, new research suggests. c-Jun belongs to a larger family of transcription factors, DNA-binding factors, known as Activator Protein-1 (AP-1). Previous studies have identifie…
- And the Winner Is...Dr. Junko Takeshita of University of Pennsylvania Wins 2020 Childhood Eczema Challenge Granthttps://practicaldermatology.com/news/and-the-winner-isdr-junko-takeshita-of-university-of-pennsylvania-wins-2020-childhood-eczema-challenge-grant/2460481/The National Eczema Association (NEA) and the Pediatric Dermatology Research Alliance’s (PeDRA) inaugural Childhood Eczema Challenge Grant goes to Junko Takeshita, MD, PhD, MSCE of the University of Pennsylvania Perelman School of Medicine. The grant of $50,000 will commence in August 2020. NEA a…
- Juvéderm Voluma XC Approved for Enhancement of the Chin Regionhttps://practicaldermatology.com/news/juvederm-voluma-xc-approved-for-enhancement-of-the-chin-region/2460426/The FDA has approved a new indication for Juvéderm Voluma XC for the augmentation of the chin region to improve the chin profile in adults over the age of 21. The Juvéderm Collection of Fillers has the broadest portfolio of specifically tailored treatment options, and this latest approval marks the…
- FDA Approves Ortho Dermatologics' Jublia to Treat Onychomycosis in Patients As Young As Six Years Oldhttps://practicaldermatology.com/news/fda-approves-ortho-dermatologics-jublia-to-treat-onychomycosis-in-patients-as-young-as-six-years-old/2460371/Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics received FDA approval for a supplemental New Drug Application (sNDA) for Jublia (efinaconazole) topical solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, which extends the age range includ…
- Allergan Rolls Out New DTC Juvéderm Lips Campaignhttps://practicaldermatology.com/news/allergan-rolls-out-new-dtc-juvederm-lips-campaign/2460281/Allergan is launching its new direct-to-consumer campaign for Juvéderm lips with ads and creative deploying across TV, social media, and digital advertising. As part of the new campaign, New York City-based facial plastic surgeon Dara Liotta, MD, reality television personality Audrina Patridge, an…
- FDA Approves Juvéderm Voluma XC For Mid-Face Injection Via Cannulahttps://practicaldermatology.com/news/fda-approves-juvederm-voluma-xc-for-mid-face-injection-via-cannula/2460137/Allergan’s Juvéderm Voluma XC is now U.S. Food and Drug Administration (FDA)-approved for cheek augmentation in the mid-face in adults over 21 with a TSK Steriglide cannula. This cannula features a patented tip design with a near-tip delivery port for precise product placement. Within the Juvéder…
- New Xeomin "Later Haters" Campaign Urges Women to “X” Out Judgmenthttps://practicaldermatology.com/news/new-xeomin-later-haters-campaign-aims-to-x-out-judgment/2457487/Merz Americas is launching a new advertising campaign for Xeomin (incobotulinumtoxinA) called “Later Haters,” which urges women to “X out” judgment, stop apologizing for caring about how they look and put an end to feeling guilty about their self-care routines. The new advertising campaign will b…